Efficient adenovector CD40 ligand immunotherapy of canine malignant melanoma

Journal of Immunotherapy

Volumn 31, Issue 4, 2008, Pages 377-384

  Von Euler, Henrik ^a   Sadeghi, Arian ^b   Carlsson, Björn ^b   Rivera, Patricio ^a   Loskog, Angelica ^b   Segall, Thomas ^c   Korsgren, Olle ^b   Tötterman, Thomas H ^b,d  

^a SWEDISH UNIVERSITY OF AGRICULTURAL SCIENCES   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c NATIONAL VETERINARY INSTITUTE   (Sweden)

^d UPPSALA UNIVERSITY   (Sweden)

Author keywords

Canine malignant melanoma; CD40L; Immunotherapy; Malignant melanoma

Indexed keywords

ADENOVIRUS VECTOR; CD40 LIGAND;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPSY; B LYMPHOCYTE; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; CONJUNCTIVA TUMOR; CYTOREDUCTIVE SURGERY; DISEASE FREE SURVIVAL; DOG; DRUG EFFICACY; FEMALE; LYMPHOCYTE ACTIVATION; LYMPHOCYTIC INFILTRATION; MALE; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; METASTASIS; MINIMAL RESIDUAL DISEASE; MOUTH TUMOR; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TREATMENT OUTCOME; TUMOR IMMUNITY; TUMOR LOCALIZATION; TUMOR REGRESSION; VIRAL GENE DELIVERY SYSTEM;

ADENOVIRIDAE; ANIMALS; CD40 LIGAND; CONJUNCTIVAL NEOPLASMS; DOG DISEASES; DOGS; FEMALE; GENETIC VECTORS; IMMUNOTHERAPY, ACTIVE; INTERFERON TYPE II; MALE; MELANOMA; MOUTH NEOPLASMS; REMISSION INDUCTION; T-LYMPHOCYTES; TRANSDUCTION, GENETIC;

EID: 42649091115     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e31816a812d     Document Type: Article

References (32)

1. Smith SH, Goldschmidt MH, McManus PM. A comparative review of melanocytic neoplasms. Vet Pathol. 2002;39:651-678.
2. Wolfe LG, Oliver JL, Smith BB, et al. Biologic characterization of canine melanoma cell lines. Am J Vet Res. 1987;48:1642-1648.
3. Sulaimon SS, Kitchell BE. The basic biology of malignant melanoma: molecular mechanisms of disease progression and comparative aspects. J Vet Intern Med. 2003;17:760-772.
4. Koenig A, Bianco SR, Fosmire S, et al. Expression and significance of p53, rb, p21/waf-1, p16/ink-4a, and PTEN tumor suppressors in canine melanoma. Vet Pathol. 2002;39:458-472.
5. Serra M, Rabanal RM, Miquel L, et al. Differential expression of CD44 in canine melanocytic tumours. J Comp Pathol. 2004;130:171-180.
6. Ragnarsson-Olding BK. Primary malignant melanoma of the vulva - an aggressive tumor for modeling the genesis of non-UV light-associated melanomas. Acta Oncol. 2004;43:421-435.
7. Ohashi E, Inoue K, Kagechika H, et al. Effect of natural and synthetic retinoids on the proliferation and differentiation of three canine melanoma cell lines. J Vet Med Sci. 2002;64:169-172.
8. Catchpole B, Gould SM, Kellett-Gregory LM, et al. Development of a multiple-marker polymerase chain reaction assay for detection of metastatic melanoma in lymph node aspirates of dogs. Am J Vet Res. 2003;64:544-549.
9. Dow SW, Elmslie RE, Willson AP, et al. In vivo tumor transfection with superantigen plus cytokine genes induces tumor regression and prolongs survival in dogs with malignant melanoma. J Clin Invest. 1998;101:2406-2414.
10. MacEwen EG, Kurzman ID, Vail DM, et al. Adjuvant therapy for melanoma in dogs: results of randomized clinical trials using surgery, liposome-encapsulated muramyl tripeptide, and granulocyte macrophage colony-stimulating factor. Clin Cancer Res. 1999;5:4249-4258.
11. Houghton AN, Meyers ML, Chapman PB. Medical treatment of metastatic melanoma. Surg Clin North Am. 1996;76:1343-1354.
12. Sirott MN, Bajorin DF, Wong GY, et al. Prognostic factors in patients with metastatic malignant melanoma. A multivariate analysis. Cancer. 1993;72:3091-3098.
13. Bostock DE. Prognosis after surgical excision of canine melanomas. Vet Pathol. 1979;16:32-40.
14. Harvey HJ, MacEwen EG, Braun D, et al. Prognostic criteria for dogs with oral melanoma. J Am Vet Med Assoc. 1981;178:580-582.
15. MacEwen EG, Patnaik AK, Harvey HJ, et al. Canine oral melanoma: comparison of surgery versus surgery plus Corynebacterium parvum. Cancer Invest. 1986;4:397-402.
16. Bergman PJ, McKnight J, Novosad A, et al. Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: a phase I trial. Clin Cancer Res. 2003;9:1284-1290.
17. Knapp DW, Waters DJ. Naturally occurring cancer in pet dogs: important models for developing improved cancer therapy for humans. Mol Med Today. 1997;3:8-11.
18. MacEwen EG. Spontaneous tumors in dogs and cats: models for the study of cancer biology and treatment. Cancer Metastasis Rev. 1990;9:125-136.
19. Vail DM, MacEwen EG. Spontaneously occurring tumors of companion animals as models for human cancer. Cancer Invest. 2000;18:781-792.
20. Loskog A, Totterman TH, Bohle A, et al. In vitro activation of cancer patient-derived dendritic cells by tumor cells genetically modified to express CD154. Cancer Gene Ther. 2002;9:846-853.
21. Loskog A, Bjorkland A, Brown MP, et al. Potent antitumor effects of CD154 transduced tumor cells in experimental bladder cancer. J Urol. 2001;166:1093-1097.
22. Loskog A, Dzojic H, Vikman S, et al. Adenovirus CD40 ligand gene therapy counteracts immune escape mechanisms in the tumor microenvironment. J Immunol. 2004;172:7200-7205.
23. Loskog AS, Fransson ME, Totterman TT. AdCD40L gene therapy counteracts T regulatory cells and cures aggressive tumors in an orthotopic bladder cancer model. Clin Cancer Res. 2005;11:8816-8821.
24. Loskog A, Giandomenico V, Rossig C, et al. Addition of the CD28 signaling domain to chimeric T-cell receptors enhances chimeric T-cell resistance to T regulatory cells. Leukemia. 2006;20:1819-1828.
25. Loskog A, Totterman TH. CD40L - a multipotent molecule for tumor therapy. Endocr Metabol Immune Disord Drug Targets. 2007;7:23-28.
26. Owen LN, ed. TNM Classification of Tumours in Domestic Animals. 1 edn. Geneva, Switzerland: World Health Organization; 1980.
27. Loskog A, Ninalga C, Totterman TH. Dendritic cells engineered to express CD40L continuously produce IL12 and resist negative signals from Tr1/Th3 dominated tumors. Cancer Immunol Immunother. 2006;55:588-597.
28. Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002;298:850-854.
29. Dudley ME, Wunderlich JR, Yang JC, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol. 2005;23:2346-2357.
30. Bergman PJ, Camps-Palau MA, McKnight JA, et al. Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the Animal Medical Center. Vaccine. 2006;24:4582-4585.
31. Liao JC, Gregor P, Wolchok JD, et al. Vaccination with human tyrosinase DNA induces antibody responses in dogs with advanced melanoma. Cancer Immun. 2006;6:8.
32. Thamm DH, Kurzman ID, Macewen EG, et al. Intralesional lipid-complexed cytokine/superantigen immunogene therapy for spontaneous canine tumors. Cancer Immunol Immunother. 2003;52:473-480.